• Downhill Running, Caloric Restriction, and Muscle Atrophy

  2026-09-17

  The reference study identifies macrophage polarization through the TRIB3-AKT pathway as a mechanistic link between downhill running, caloric restriction, insulin sensitivity, and skeletal muscle maintenance in insulin-resistant mice. Its combined animal, co-culture, and molecular perturbation strategy provides a useful framework for studying how exercise and diet influence muscle regeneration, while also illustrating the need to interpret CCK-8 data alongside functional and molecular endpoints.

• Cl-Amidine: Practical PAD4 Inhibition Workflows

  2026-09-17

  Cl-Amidine enables a staged strategy that separates direct PAD4 enzyme inhibition from cellular histone-citrullination effects and disease-model phenotypes. This guide combines formulation guidance, assay design, cross-domain interpretation, and troubleshooting for cancer research, rheumatoid arthritis research, and septic shock studies.

• USP36–Snail1 Signaling in Ribotoxic Stress

  2026-09-16

  The reference study identifies a JNK–USP36–Snail1 pathway that enables solid tumor cells to maintain ribosome biogenesis and survive ribotoxic stress. Its findings explain why homoharringtonine can be effective in leukemia yet comparatively weak against solid tumors, while providing a rationale for pathway-directed combination strategies.

• MK-5108: Translating Aurora A Biology

  2026-09-16

  A translational framework for using MK-5108 (VX-689) to connect AURKA biology, retinoblastoma evidence, selective kinase pharmacology, and reproducible cancer research workflows.

• JIB-04 Targets Colorectal Cancer Stem Cells

  2026-09-15

  The reference study identifies JIB-04 as a small-molecule inhibitor that suppresses colorectal cancer stem-cell self-renewal, tumor-sphere formation, invasion, and tumorigenicity. Integrated transcriptomic and Wnt/β-catenin reporter analyses connect these effects with reduced stemness-associated signaling, while also highlighting the limits of interpreting a pan-selective demethylase inhibitor as a single-target treatment.

• AT-406: Practical IAP Apoptosis Workflows

  2026-09-15

  AT-406 (SM-406) gives cancer researchers a practical route to interrogate IAP-controlled apoptosis, from concentration-response studies to chemotherapy-sensitization experiments. Its oral bioavailability and defined mechanistic readouts also support translation from cell assays into preclinical xenograft workflows.

• Moxidectin: From Anthelmintic to Assay Insight

  2026-09-14

  Moxidectin is a macrocyclic lactone anthelmintic with established veterinary utility and emerging antifungal relevance. This evidence-focused guide explains how its Candida–polyene synergy should shape assay design, interpretation, and translational expectations.

• LMO2–LDB1 Signaling in Acute Myeloid Leukemia

  2026-09-14

  The reference study identifies an LMO2/LDB1 protein complex as an important transcriptional driver of acute myeloid leukemia (AML) cell maintenance. Through gene perturbation, protein-interaction analysis, transcriptomics, chromatin profiling, and in vivo validation, the authors show that LDB1 supports AML proliferation and survival partly through LMO2-regulated programs.

• Deferasirox: Iron Chelation Research Workflows

  2026-09-13

  Deferasirox offers a practical way to perturb labile iron while connecting iron-overload biology with ferroptosis-focused cancer research. This workflow guide covers concentration design, oxygen-aware interpretation, ferroptosis readouts, and troubleshooting for HCC and hematopoietic models.

• Masitinib (AB1010): KIT/PDGFR Workflow Guide

  2026-09-12

  Masitinib (AB1010), SKU A2942, is a DMSO-compatible tyrosine kinase inhibitor for focused KIT, PDGFRα, PDGFRβ, mast-cell, and selected GIST research. It is appropriate for defined cellular or biochemical workflows, but not for aqueous or ethanol-based assays, broad-spectrum kinase studies, or clinical treatment decisions.

• BMS 309403: A Practical FABP4 Inhibitor Workflow

  2026-09-11

  BMS 309403 provides a selective pharmacological entry point for testing how FABP4 connects fatty acid handling, macrophage inflammation, and foam cell formation. This workflow translates mechanistic findings into reproducible cell-based assays for atherosclerosis, metabolic disease, and type 2 diabetes research.

• HyperFluor™ 488 Antibody for Hypoxia Assays

  2026-09-11

  Learn how HyperFluor™ 488 Rabbit Anti-Goat IgG (H+L) Antibody supports spatially resolved hypoxia research, from PHD2/HIF-1α/EPO staining to orthogonal tissue validation. This guide translates the ginsenoside study into practical decisions for fluorescence, Western blot, flow cytometry, and histology workflows.

• Carbapenemase Transmission in CREC Across Guangdong

  2026-09-10

  A 2025 BMC Microbiology study characterized carbapenemase-encoding genes in 54 carbapenem-resistant Enterobacter cloacae isolates from eight teaching hospitals in Guangdong, China. Its combination of gene localization, conjugation testing, mobile-element analysis, antimicrobial susceptibility testing, and ERIC-PCR links plasmid-mediated horizontal transfer with clonal dissemination and multidrug resistance.

• Wortmannin Workflows for PI3K and Autophagy

  2026-09-10

  Wortmannin enables controlled interrogation of PI3K-dependent signaling, autophagy, and cell death in infection and cancer models. This workflow connects macrophage experiments inspired by Entamoeba histolytica research with practical controls, dosing logic, and troubleshooting for reproducible pathway studies.

• Hematoxylin and Eosin Staining Kit Guide

  2026-09-09

  The Hematoxylin and Eosin Staining Kit (SKU K1142) provides ready-to-use hematoxylin and eosin solutions for visualizing nuclei, cytoplasm, extracellular matrix, and overall tissue architecture. It is intended for research workflows involving paraffin-embedded or frozen sections and cytological preparations, not clinical diagnosis or medical use.

8479 records 1/566 page Next 12345 下5页 Last page